A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 11 Jul 2015
At a glance
- Drugs Docetaxel; Prednisone; Sepantronium bromide
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 20 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 20 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Sep 2009 Planned end date changed from 1 Dec 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.